Comparative Pharmacology
Head-to-head clinical analysis: CEFADYL versus CEFOBID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFADYL versus CEFOBID.
CEFADYL vs CEFOBID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bactericidal; inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin activation.
Cefoperazone is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting peptidoglycan cross-linking and causing cell lysis.
1-2 g IV/IM every 6 hours for moderate to severe infections; maximum 12 g/day.
2-4 g/day IV/IM divided q12h; severe infections: 6-12 g/day IV divided q8-12h
None Documented
None Documented
30-60 minutes in adults with normal renal function; prolonged to 10-20 hours in end-stage renal disease. Requires dose adjustment for CrCl <30 mL/min.
2 hours (prolonged in hepatic impairment and neonates).
Renal: 90-95% unchanged via glomerular filtration and tubular secretion. Biliary: <1%. Fecal: minimal.
Primarily renal (80-90% unchanged in urine) and biliary (10-20%).
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic